Shenzhen Shenxin Biotechnology Co., Ltd
Clinical trials sponsored by Shenzhen Shenxin Biotechnology Co., Ltd, explained in plain language.
-
New mRNA vaccine targets RSV in first human trial
⭐️ VACCINE ⭐️ OngoingThis early-stage study tests a new mRNA vaccine (IN006) designed to protect against respiratory syncytial virus (RSV). About 240 healthy adults aged 18 and older will receive one of three vaccine doses or a placebo. Researchers will monitor side effects and measure immune respons…
Phase: PHASE1 • Sponsor: Shenzhen Shenxin Biotechnology Co., Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated May 26, 2026 09:57 UTC
-
New RSV vaccine trial aims to shield seniors from severe lung infections
⭐️ VACCINE ⭐️ OngoingThis study tests a new mRNA vaccine called IN006 to protect against respiratory syncytial virus (RSV) in healthy adults aged 60 and older. About 500 participants will receive either the vaccine or a placebo, and researchers will monitor side effects and immune responses for up to…
Phase: PHASE2 • Sponsor: Shenzhen Shenxin Biotechnology Co., Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated May 26, 2026 09:53 UTC